Company Analysis
Sign in

OPKO Health, Inc. (OPK)

Nasdaq: OPK · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.2
◀ Past 5.3● Present 6.2▶ Future 3.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

266 patents granted to the 19 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to OPKO Health, Inc.’s names, not what it holds today.

Patents granted
266
258 utility, 8 design, 1976 to Dec 31, 2025
Granted in 2025
7
Against 6 in 2024 and 8 in 2023
Applications published
281
9 of them in 2025
Names they are printed under
19
a subsidiary, its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals25
Biotechnology5
Analysis of biological materials3
Chemical engineering2
Computer technology2
Medical technology1
Measurement1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name19 counted
CuRNA, Inc. a subsidiary
US, as the owner printed on each patent
111 granted
35 published
OPKO Diagnostics, LLC a subsidiary
US, as the owner printed on each patent
57 granted
55 published
CuRNA, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
72 published
OPKO BIOLOGICS LTD. a subsidiary
IL, as the owner printed on each patent
26 granted
29 published
OPKO Health, Inc. its own name
US, as the owner printed on each patent
26 granted
16 published
EIRGEN PHARMA LTD. a subsidiary
IE, as the owner printed on each patent
16 granted
1 published
Transition Therapeutics, Inc. a subsidiary
CA, as the owner printed on each patent
7 granted
8 published
OPKO Pharmaceuticals, LLC a subsidiary
US, as the owner printed on each patent
9 granted
5 published
EIRGEN PHARMA LTD. a subsidiary
named as the applicant on its applications, in IE
0 granted
13 published
OPKO Health, Inc. its own name
named as the applicant on its applications, in US
0 granted
13 published
OPKO BIOLOGICS LTD. a subsidiary
named as the applicant on its applications, in IL
0 granted
11 published
ModeX Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
10 published
BioReference Health, LLC a subsidiary
US, as the owner printed on each patent
6 granted
2 published
Cytoclonal Pharmaceutics, Inc. a former name
US, as the owner printed on each patent
6 granted
0 published
OPKO Pharmaceuticals, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
OPKO Diagnostics, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
FineTech Pharmaceutical Ltd. a subsidiary
IL, as the owner printed on each patent
1 granted
1 published
BioReference Health, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Exegenics Inc. a former name
US, as the owner printed on each patent
1 granted
0 published
Names not counted (5)
OPKO Renal, LLC
Most of its patents print US; this name counts in CA. 17 granted and 1 published under it are not counted.
OPKO Renal, LLC
Most of its patents print US; this name counts in CA. 0 granted and 16 published under it are not counted.
ModeX Therapeutics, Inc.
Most of its patents print CH; this name counts in US. 1 granted and 0 published under it are not counted.
Transition Therapeutics, Corp. ULC
No country is printed for it. 0 granted and 1 published under it are not counted.
Transition Therapeutics, Corp. ULC
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,510,543Prostate antigen standards and uses thereofAnalysis of biological materialsOPKO Diagnostics, LLC
Nov 25, 202512,478,631Stabilized modified release vitamin D formulation and method of administering samePharmaceuticalsEIRGEN PHARMA LTD.
Oct 14, 202512,441,776Oxyntomodulin peptide analog formulationsPharmaceuticalsEIRGEN PHARMA LTD.
Oct 7, 202512,433,842Pediatric dosage forms, methods of making and usingPharmaceuticalsEIRGEN PHARMA LTD.
Jun 10, 202512,326,453Compositions and methods for active surveillance of prostate cancerComputer technologyOPKO Diagnostics, LLC
Jan 28, 202512,208,106Methods of vitamin D treatmentPharmaceuticalsEIRGEN PHARMA LTD.
Jan 21, 202512,203,113Long-acting coagulation factors and methods of producing sameBiotechnologyOPKO BIOLOGICS LTD.
Nov 5, 202412,133,917Pediatric dosage forms, methods of making and usingPharmaceuticalsEIRGEN PHARMA LTD.
Oct 29, 202412,131,802Methods and apparatuses for predicting risk of prostate cancer and prostate gland volumeAnalysis of biological materialsOPKO Diagnostics, LLC
Jul 9, 202412,029,780Long-acting polypeptides and methods of producing and administering sameBiotechnologyOPKO BIOLOGICS LTD.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0326823Antigen Binding Polypeptides, Polypeptide Complexes and Methods of Use ThereofBiotechnologyModeX Therapeutics, Inc.
Oct 23, 20252025/0326814MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOFPharmaceuticalsOPKO BIOLOGICS LTD.
Aug 14, 20252025/0255985PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEMPharmaceuticalsModeX Therapeutics, Inc.
Jun 19, 20252025/0197481Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIVBiotechnologyModeX Therapeutics, Inc.
Jun 12, 20252025/0186464METHODS OF TREATING VITAMIN D INSUFFICIENCY IN CHRONIC KIDNEY DISEASEPharmaceuticalsEIRGEN PHARMA LTD.
May 22, 20252025/0161481TARGETED LNP DELIVERYPharmaceuticalsModeX Therapeutics, Inc.
May 8, 20252025/0144119ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTIONPharmaceuticalsEIRGEN PHARMA LTD.
Mar 20, 20252025/0092116METHODS OF PRODUCING LONG-ACTING COAGULATION FACTORSBiotechnologyOPKO BIOLOGICS LTD.
Jan 23, 20252025/0025423PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USINGPharmaceuticalsEIRGEN PHARMA LTD.
May 23, 20242024/0166710METHODS OF ADMINISTERING LONG-ACTING GROWTH HORMONE POLYPEPTIDESPharmaceuticalsOPKO BIOLOGICS LTD.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Biotechnology 5 · Organic fine chemistry 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OPK · research, not advice